研究者詳細 - 枝園　忠彦

論文 - 枝園　忠彦

分割表示 275 件中 81 - 100 件目／全件表示 >>

転移・再発乳癌における遺伝子パネル検査の観察研究REIWA studyの中間解析

増田紘子, 多田寛, 安立弥生, 岩谷胤生, 上本康明, 北川大, 古川孝広, 相良安昭, 枝園忠彦, 原文堅, 八十島宏行, 吉村健一, 岩田広治, 増田慎三

日本癌治療学会学術集会抄録集 60回 O11 - 5 2022年10月

男女を問わず外科医が輝き続けるためにステレオタイプ・スレットという問題とニュースレターの果たす役割

竹原裕子, 溝尾妙子, 小林純子, 坂本美咲, 新田薫, 工藤由里絵, 安井和也, 菊池覚次, 黒田新士, 吉田龍一, 岡崎幹生, 枝園忠彦, 山根正修, 小谷恭弘, 豊岡伸一, 笠原真悟, 土井原博義, 藤原俊義

日本外科学会雑誌 123 ( 5 ) 501 - 502 2022年9月

【乳癌に対する乳頭温存乳房全切除術施行後の局所再発パターン別予後レビュー】

山口亜友, 石飛真人, 河手敬彦, 枝園忠彦, 関大仁

Oncoplastic Breast Surgery 7 ( 3 ) 69 - 71 2022年9月

記述言語：日本語出版者・発行元：(一社)日本乳房オンコプラスティックサージャリー学会

われわれは,乳頭温存乳房全切除術施行後の乳癌患者における局所再発パターン別予後に関する論文のレビューを行ったので報告する。(著者抄録)

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2022&ichushi_jid=J06905&link_issn=&doc_id=20221006150002&doc_link_id=10.20699%2Fjopbs.7.3_69&url=https%3A%2F%2Fdoi.org%2F10.20699%2Fjopbs.7.3_69&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

Predictive value of immune genomic signatures from breast cancer cohorts containing data for both response to neoadjuvant chemotherapy and prognosis after surgery.

Yidan Zhu, Takayuki Iwamoto, Yukiko Kajiwara, Yuko Takahashi, Mariko Kochi, Tadahiko Shien, Naruto Taira, Shinichi Toyooka, Hiroyoshi Doihara

Breast cancer (Tokyo, Japan) 30 ( 1 ) 56 - 67 2022年8月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Previous studies of immune genomic signatures (IGSs) in breast cancer have attempted to predict the response to chemotherapy or prognosis and were performed using different patient cohorts. The purpose of this study was to evaluate the predictive functions of various IGSs using the same patient cohort that included data for response to chemotherapy as well as the prognosis after surgery. METHODS: We applied five previously described IGS models in a public dataset of 508 breast cancer patients treated with neoadjuvant chemotherapy. The prognostic and predictive values of each model were evaluated, and their correlations were compared. RESULTS: We observed a high proportion of expression concordance among the IGS models (r: 0.56-1). Higher scores of IGSs were detected in aggressive breast cancer subtypes (basal and HER2-enriched) (P < 0.001). Four of the five IGSs could predict chemotherapy responses and two could predict 5-year relapse-free survival in cases with hormone receptor-positive (HR +) tumors. However, the models showed no significant differences in their predictive abilities for hormone receptor-negative (HR-) tumors. CONCLUSIONS: IGSs are, to some extent, useful for predicting prognosis and chemotherapy response; moreover, they show substantial agreement for specific breast cancer subtypes. However, it is necessary to identify more compelling biomarkers for both prognosis and response to chemotherapy in HR- and HER2 + cases.

DOI： 10.1007/s12282-022-01397-3

PubMed

researchmap

Gene Expression Profiling between Patient Groups with High and Low Ki67 Levels after Short-term Preoperative Aromatase Inhibitor Treatment for Breast Cancer.

Yukiko Kajiwara, Takayuki Iwamoto, Yidan Zhu, Mariko Kochi, Tadahiko Shien, Naruto Taira, Hiroyoshi Doihara, Shinichi Toyooka

Acta medica Okayama 76 ( 4 ) 399 - 408 2022年8月

記述言語：英語掲載種別：研究論文（学術雑誌）

According to a recent report, a low Ki67 level after short-term preoperative hormone therapy (post-Ki67) might suggest a more favorable prognosis compared with a high post-Ki67 level in patients with hormone receptorpositive/human epidermal growth factor 2-negative (HR+/HER2-) breast cancer with high levels of Ki67. This study aimed to evaluate the pre-treatment genetic differences between these two patient groups. Forty-five luminal B-like patients were stratified into two groups, namely, a group with high (H→H) and one with low (H→L) Ki67 levels after short-term preoperative aromatase inhibitor (AI) treatment. We compared pre-treatment gene expression profiles between the two groups. In gene level analysis, there was no significant difference between the two groups by the class comparison test. In pathway analysis, five metabolism-related gene sets were significantly upregulated in the H→L group (p≤0.05). In the search for novel targets, five genes (PARP, BRCA2, FLT4, CDK6, and PDCD1LG2) showed significantly higher expression in the H→H group (p≤0.05). Several metabolism-related pathways were associated with sensitivity to AI. In the future, it will be necessary to seek out new therapeutic strategies for the poor prognostic group with high post-Ki67.

DOI： 10.18926/AMO/63894

PubMed

researchmap

Drug repositioning of tranilast to sensitize a cancer therapy by targeting cancer-associated fibroblast. 国際誌

Kosuke Ochi, Ken Suzawa, Yin Min Thu, Fumiaki Takatsu, Shimpei Tsudaka, Yidan Zhu, Kentaro Nakata, Tatsuaki Takeda, Kazuhiko Shien, Hiromasa Yamamoto, Mikio Okazaki, Seiichiro Sugimoto, Tadahiko Shien, Yoshiharu Okamoto, Shuta Tomida, Shinichi Toyooka

Cancer science 113 ( 10 ) 3428 - 3436 2022年7月

記述言語：英語掲載種別：研究論文（学術雑誌）

Cancer-associated fibroblasts (CAFs) are a major component of the tumor microenvironment that mediate resistance of cancer cells to anticancer drugs. Tranilast is an antiallergic drug that suppresses the release of cytokines from various inflammatory cells. In this study, we investigated the inhibitory effect of tranilast on the interactions between non-small cell lung cancer (NSCLC) cells and the CAFs in the tumor microenvironment. Three EGFR-mutant NSCLC cell lines, two KRAS-mutant cell lines and three CAFs derived from NSCLC patients were used. To mimic the tumor microenvironment, the NSCLC cells were co-cultured with the CAFs in vitro, and the molecular profiles and sensitivity to molecular targeted therapy were assessed. Crosstalk between NSCLC cells and CAFs induced multiple biological effects on the NSCLC cells both in vivo and in vitro, including activation of the STAT3 signaling pathway, promotion of xenograft tumor growth, induction of epithelial-mesenchymal transition (EMT), and acquisition of resistance to molecular-targeted therapy, including of EGFR-mutant NSCLC cells to osimertinib and of KRAS-mutant NSCLC cells to selumetinib. Treatment with tranilast led to inhibition of IL-6 secretion from the CAFs, which, in turn, resulted in inhibition of CAF-induced phospho-STAT3 upregulation. Tranilast also inhibited CAF-induced EMT in the NSCLC cells. Finally, combined administration of tranilast with molecular-targeted therapy reversed the CAF-mediated resistance of the NSCLC cells to the molecular-targeted drugs, both in vitro and in vivo. Our results showed that combined administration of tranilast with molecular-targeted therapy is a possible new treatment strategy to overcome drug resistance caused by cancer- CAF interaction.

DOI： 10.1111/cas.15502

PubMed

researchmap

乳癌内分泌療法の課題と展望転移乳癌に対する治療戦略としての局所療法と内分泌療法の課題と展望

枝園忠彦, 戸嶋圭, 中本翔伍, 宇野摩耶, 吉岡遼, 鈴木陽子, 高橋侑子, 岩本高行, 岩谷胤生

日本内分泌外科学会雑誌 39 ( Suppl.1 ) S126 - S126 2022年6月

転移・再発乳癌における遺伝子パネル検査F1CDxとF1LCDxの治療方針決定に与える影響を検討する観察研究

多田寛, 増田紘子, 安立弥生, 岩谷胤生, 上本康明, 大谷陽子, 梶原友紀子, 北川大, 古川孝広, 相良安昭, 枝園忠彦, 田辺裕子, 谷岡真樹, 服部正也, 原文堅, 八十島宏行, 吉村健一, 岩田広治, 増田慎三

日本乳癌学会総会プログラム抄録集 30回 PD7 - 2 2022年6月

乳房再建術が周術期の炎症性サイトカインに及ぼす影響についての検討

向井裕子, 平成人, 北口陽平, 中桐僚子, 雑賀美帆, 河内麻里子, 岩本高行, 枝園忠彦, 土井原博義, 木股敬裕

日本乳癌学会総会プログラム抄録集 30回 EP13 - 9 2022年6月

当科におけるBRCA1/2病的バリアント保持者へのリスク低減乳房切除術の現状

間森智加, 河内麻里子, 大谷悠介, 吉岡遼, 藤原みわ, 中本翔伍, 鈴木陽子, 宇野摩耶, 鳩野みなみ, 安部優子, 高橋侑子, 岩本高行, 枝園忠彦, 平成人, 土井原博義

日本乳癌学会総会プログラム抄録集 30回 PO15 - 5 2022年6月

乳癌内分泌療法の課題と展望転移乳癌に対する治療戦略としての局所療法と内分泌療法の課題と展望

枝園忠彦, 戸嶋圭, 中本翔伍, 宇野摩耶, 吉岡遼, 鈴木陽子, 高橋侑子, 岩本高行, 岩谷胤生

日本内分泌外科学会雑誌 39 ( Suppl.1 ) S126 - S126 2022年6月

AYA世代患者の乳房再建と妊娠・出産

中桐僚子, 雑賀美帆, 向井裕子, 北口陽平, 渡部聡子, 高橋侑子, 河内麻里子, 岩本高行, 枝園忠彦, 平成人, 露無祐子, 土井原博義, 木股敬裕

日本乳癌学会総会プログラム抄録集 30回 PO17 - 1 2022年6月

対側リスク低減乳房切除術で非浸潤性乳管癌が発見された遺伝性乳癌卵巣癌症候群の1例

中川里沙子, 宇野摩耶, 間森智加, 河内麻里子, 大谷悠介, 吉岡遼, 藤原みわ, 中本翔伍, 鈴木陽子, 安部優子, 鳩野みなみ, 高橋侑子, 都地友紘, 岩本高行, 枝園忠彦, 平成人, 柳井広之, 土井原博義

日本乳癌学会総会プログラム抄録集 30回 EP11 - 68 2022年6月

当院における甲状腺がん遺伝子パネル検査の実施経験

高橋侑子, 枝園忠彦, 土井原博義

日本内分泌外科学会雑誌 39 ( Suppl.1 ) S180 - S180 2022年6月

臨床研究におけるエンドポイントとしてのHRQOLの意義 Emoji Sticker scaleを用いた患者報告アウトカムの妥当性と信頼性を検証する調査研究

鈴木陽子, 平成人, 間森智加, 大谷悠介, 吉岡遼, 藤原みわ, 中本翔佑, 宇野摩耶, 安部優子, 鳩野みなみ, 高橋侑子, 岩本高行, 枝園忠彦, 木川雄一郎, 上村夕香理, 萩原康博, 山本精一郎, 土井原博義

日本乳癌学会総会プログラム抄録集 30回 SY11 - 4 2022年6月

地域における乳がん患者に対する妊孕性温存の現状と課題

枝園忠彦, 露無裕子, 樫野千明, 中塚幹也, 鳩野みなみ, 間森智花, 宇野摩耶, 中本翔伍, 吉岡遼, 藤原みわ, 鈴木陽子, 高橋侑子, 河内麻里子, 岩本高行, 平成人, 土井原博義

日本乳癌学会総会プログラム抄録集 30回 OS9 - 3 2022年6月

(第26回)乳癌学会班研究「乳房再建の安全性と予後に関する研究」報告

枝園忠彦, 野木裕子, 山内智香子, 森弘樹, 石飛真人, 笹田伸介, 荻谷朗子, 近藤直人, 志茂彩華, 寺田かおり, 雑賀美帆, 関大仁, 名倉直美, 櫻井照久, 成井一隆, 新倉直樹

日本乳癌学会総会プログラム抄録集 30回 np66 - np66 2022年6月

腋窩リンパ節転移陽性乳癌に対する一次乳房再建の適応と安全性乳がん治療再建センターにおける腋窩リンパ節転移陽性乳癌に対する一次乳房再建

枝園忠彦, 岡美苗, 戸嶋圭, 中本翔伍, 宇野摩耶, 吉岡遼, 鈴木陽子, 大谷悠介, 高橋侑子, 岩本高行, 岩谷胤生

日本外科系連合学会誌 47 ( 3 ) 374 - 374 2022年5月

腋窩リンパ節転移陽性乳癌に対する一次乳房再建の適応と安全性乳がん治療再建センターにおける腋窩リンパ節転移陽性乳癌に対する一次乳房再建

枝園忠彦, 岡美苗, 戸嶋圭, 中本翔伍, 宇野摩耶, 吉岡遼, 鈴木陽子, 大谷悠介, 高橋侑子, 岩本高行, 岩谷胤生

日本外科系連合学会誌 47 ( 3 ) 374 - 374 2022年5月

Management of breast cancer in older patients. 国際誌

Masataka Sawaki, Akihiko Shimomura, Tadahiko Shien, Hiroji Iwata

Japanese journal of clinical oncology 52 ( 7 ) 674 - 681 2022年4月

記述言語：英語掲載種別：研究論文（学術雑誌）

Japanese women have the highest life expectancy in the world and breast cancer is the most prevalent cancer among them. However, little data are available to support the evidence-based clinical management due to the fact that older adults are commonly excluded from most clinical trials. In Japan the rate of other cause of death in older patient was about a half, then we should consider whether or not breast cancer may affect the patient's life expectancy to avoid either overtreatment or undertreatment. Although management principles in older patients may be similar with those of younger age, these differences would be caused by relatively short life expectancy, some comorbidity, drug interactions and low functional status. Then, their treatment needs to be individualized. To this end, employing a comprehensive geriatric assessment may be advantageous, which enables to evaluate patient vulnerability from several different aspects, to predict adverse events of chemotherapy and to identify geriatric problems in advance so that extra support and modified treatment can be provided. Before treatment we should assess the patient's goals and values regarding the management of the cancer, especially on balancing survival benefit with immediate quality of life impairment due to anti-cancer therapy. In Japan Clinical Oncology Group (JCOG) , a randomized controlled trial for older patients with advanced stage HER2-positive breast cancer is ongoing as an inferiority design including geriatric assessment (JCOG1607, HARB TEA study). Best practice, current management and how to approach decision making in older patients with breast cancer are summarized.

DOI： 10.1093/jjco/hyac054

PubMed

researchmap

　前のページ - 次のページ　

<枝園 忠彦>

論文 - 枝園 忠彦

<枝園　忠彦>

論文 - 枝園　忠彦